[go: up one dir, main page]

PL2592072T3 - Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie - Google Patents

Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie

Info

Publication number
PL2592072T3
PL2592072T3 PL12196174T PL12196174T PL2592072T3 PL 2592072 T3 PL2592072 T3 PL 2592072T3 PL 12196174 T PL12196174 T PL 12196174T PL 12196174 T PL12196174 T PL 12196174T PL 2592072 T3 PL2592072 T3 PL 2592072T3
Authority
PL
Poland
Prior art keywords
protein tyrosine
human protein
tyrosine phosphatase
phosphatase inhibitors
inhibitors
Prior art date
Application number
PL12196174T
Other languages
English (en)
Inventor
Jeffrey Lyle Gray
Cynthia Monesa Clark
Kande K.D. Amarasinghe
Mathew Brian Maier
Ryan Nichols
Original Assignee
Aerpio Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerpio Therapeutics, Inc. filed Critical Aerpio Therapeutics, Inc.
Publication of PL2592072T3 publication Critical patent/PL2592072T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PL12196174T 2006-06-27 2007-06-27 Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie PL2592072T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81673006P 2006-06-27 2006-06-27
EP12196174.2A EP2592072B1 (en) 2006-06-27 2007-06-27 Human protein tyrosine phosphatase inhibitors and their use
EP07809907.4A EP2041102B1 (en) 2006-06-27 2007-06-27 Human protein tyrosine phosphatase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
PL2592072T3 true PL2592072T3 (pl) 2018-02-28

Family

ID=38704713

Family Applications (3)

Application Number Title Priority Date Filing Date
PL17191765T PL3323815T3 (pl) 2006-06-27 2007-06-27 Inhibitory ludzkiej białkowej fosfatazy tyrozynowej oraz sposoby zastosowania
PL12196174T PL2592072T3 (pl) 2006-06-27 2007-06-27 Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie
PL07809907T PL2041102T3 (pl) 2006-06-27 2007-06-27 Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i sposoby stosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17191765T PL3323815T3 (pl) 2006-06-27 2007-06-27 Inhibitory ludzkiej białkowej fosfatazy tyrozynowej oraz sposoby zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL07809907T PL2041102T3 (pl) 2006-06-27 2007-06-27 Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i sposoby stosowania

Country Status (20)

Country Link
US (13) US7622593B2 (pl)
EP (3) EP2592072B1 (pl)
JP (2) JP5232778B2 (pl)
KR (1) KR101155365B1 (pl)
CN (1) CN101506183B (pl)
AU (1) AU2007265453B2 (pl)
BR (1) BRPI0713570A2 (pl)
CA (1) CA2657096C (pl)
CO (1) CO6150144A2 (pl)
DK (3) DK2592072T3 (pl)
ES (3) ES2525429T3 (pl)
IL (1) IL196128A (pl)
MX (1) MX2009000288A (pl)
NZ (1) NZ574407A (pl)
PL (3) PL3323815T3 (pl)
PT (3) PT2592072T (pl)
RU (1) RU2447065C2 (pl)
SI (1) SI2041102T1 (pl)
WO (1) WO2008002569A2 (pl)
ZA (1) ZA200900559B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
EP2004697A2 (en) 2006-04-07 2008-12-24 The Procter & Gamble Company Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
US7589212B2 (en) * 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
AU2014202211B2 (en) * 2009-01-12 2016-06-02 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
AU2016203254B2 (en) * 2009-01-12 2018-09-13 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
CN109771421A (zh) * 2009-01-12 2019-05-21 爱尔皮奥治疗有限公司 治疗血管渗漏综合征的方法
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
CN102365024A (zh) * 2009-07-06 2012-02-29 阿克比治疗有限公司 用于防止癌细胞转移的化合物、组合物和方法
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
WO2011057112A1 (en) 2009-11-06 2011-05-12 Akebia Therapeutics Inc. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
EP2558452A2 (en) * 2010-04-15 2013-02-20 Novartis AG Oxazole and thiazole compounds as ksp inhibitors
US20180092883A1 (en) * 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
NZ610230A (en) * 2010-10-07 2015-07-31 Aerpio Therapeutics Inc Compositions and methods for treating ocular edema, neovascularization and related diseases
CN102408417B (zh) * 2011-09-26 2015-03-11 上海交通大学 2-取代乙烯磺酸酯类化合物及其制备方法和应用
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
MX347226B (es) * 2011-10-13 2017-04-19 Aerpio Therapeutics Inc Tratamiento de enfermedad ocular.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
HK1219836A1 (zh) 2013-03-15 2017-04-21 Aerpio Therapeutics, Inc. 用於治療眼病的組合物、製劑和方法
US9388135B2 (en) 2014-02-19 2016-07-12 Aerpio Therapeutics, Inc. Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones
EP3116503A4 (en) * 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
CN108290057A (zh) 2015-09-23 2018-07-17 爱尔皮奥治疗有限公司 用tie-2的激活剂治疗眼内压的方法
JP7107914B2 (ja) 2016-07-20 2022-07-27 アイポイント ファーマシューティカルズ， インコーポレイテッド ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体
CN106986836A (zh) * 2017-04-26 2017-07-28 毛阿龙 具有抗细菌活性的新型速激肽拮抗剂的制备方法
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
CN114269341A (zh) 2019-04-29 2022-04-01 视点制药公司 靶向施莱姆管的Tie-2激活剂
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof
US11613534B2 (en) 2019-10-29 2023-03-28 EyePoint Pharmaceuticals, Inc. Small molecule activators of Tie-2
BR112023004677A2 (pt) 2020-09-14 2023-05-09 Eyepoint Pharmaceuticals Inc Inserto ocular bioerodível para entrega de fármaco e método terapêutico

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673641A (en) * 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
US5378803A (en) * 1987-12-11 1995-01-03 Sterling Winthrop Inc. Azole-fused peptides and processes for preparation thereof
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2298325T3 (es) * 1992-03-13 2008-05-16 Biomerieux B.V. Peptidos y secuencias de acido nucleico relacionadas con el virus epstein barr.
EP0642353A1 (en) 1992-05-14 1995-03-15 Oncologix, Inc. Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5688781A (en) * 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
ATE445705T1 (de) * 1995-06-15 2009-10-15 Crucell Holland Bv Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
WO1998018914A1 (en) 1996-10-31 1998-05-07 Duke University Soluble tie2 receptor
JP2002504490A (ja) * 1998-02-19 2002-02-12 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トロンビン受容体アンタゴニストとしてのアゾールペプチド模倣体
US5980929A (en) 1998-03-13 1999-11-09 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
ES2199804T3 (es) 1999-03-26 2004-03-01 Regeneron Pharmaceuticals, Inc. Modulacion de la permeabilidad vascular por medio de activadores del receptor tie2.
EP1046715A1 (en) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
WO2000065088A2 (en) 1999-04-26 2000-11-02 Amersham Pharmacia Biotech Ab Primers for identifying typing or classifying nucleic acids
US6524583B1 (en) * 1999-04-28 2003-02-25 Board Of Regents, The University Of Texas System Antibody methods for selectively inhibiting VEGF
WO2000070030A1 (en) * 1999-05-19 2000-11-23 Amgen Inc. Crystal of a lymphocyte kinase-ligand complex and methods of use
NZ517426A (en) * 1999-08-27 2004-04-30 Sugen Inc Phosphate mimics and methods of treatment using phosphatase inhibitors
US6589758B1 (en) * 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
ES2287152T3 (es) 2000-06-23 2007-12-16 Bayer Schering Pharma Aktiengesellschaft Combinaciones y composiciones que interfieren con la funcion de vegf/receptor vegf y angiopoyetina/receptor tie, y su utilizacion (ii).
KR20030020960A (ko) * 2000-08-01 2003-03-10 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 이미다졸일 유도체
KR100519204B1 (ko) 2000-09-27 2005-10-06 더 프록터 앤드 갬블 캄파니 멜라노코르틴 수용체 리간드
AU2002335085A1 (en) 2001-10-25 2003-05-06 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
ES2305452T3 (es) * 2002-03-05 2008-11-01 Merck Frosst Canada Ltd. Inhibidores de la catepsina cisteina y proteasa.
AU2003229627A1 (en) 2002-04-08 2003-10-20 Max-Planck-Gesellschaft Zur Ve-ptp as regulator of ve-cadherin mediated processes or disorders
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US20050282814A1 (en) 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
US20040186151A1 (en) * 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
US20040167183A1 (en) 2003-02-20 2004-08-26 The Procter & Gamble Company Phenethylamino sulfamic acids
US20040242676A1 (en) 2003-05-30 2004-12-02 Alessi Thomas R. Method of mitigating the adverse effects of IL-2
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
ES2533176T3 (es) 2004-03-15 2015-04-08 Janssen Pharmaceutica Nv Proceso para preparar intermedios de compuestos útiles como moduladores de receptores opioides
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
ES2339789T3 (es) 2004-07-20 2010-05-25 Genentech, Inc. Inhibidores de proteina 4 de tipo angiopoyetina, combinaciones y su utilizacion.
US7691365B2 (en) 2004-09-28 2010-04-06 Aprogen, Inc. Methods of using chimeric coiled coil molecule to treat ischemic disease
EP3699191A1 (en) 2004-12-21 2020-08-26 MedImmune Limited Antibodies directed to angiopoietin-2 and uses thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
KR200400225Y1 (ko) 2005-08-02 2005-11-03 김기룡 자동복귀 기능을 가지는 도로교통표지판 어셈브리
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CN101370519B (zh) 2005-12-15 2013-07-24 阿斯利康(瑞典)有限公司 治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合
US7588924B2 (en) * 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
PL1991275T3 (pl) 2006-03-08 2015-04-30 Archemix Llc Aptamery wiążące dopełniacza i środki anty-C5 użyteczne w leczeniu zaburzeń ocznych
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
EP2004697A2 (en) 2006-04-07 2008-12-24 The Procter & Gamble Company Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
ZA200807978B (en) 2006-04-07 2009-08-26 Procter & Gamble Antibodies that bind human protein tyrosine phosphatase beta (HPTPBETA) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
CN101506180B (zh) 2006-06-27 2013-10-30 艾尔普罗医疗有限公司 人蛋白酪氨酸磷酸酶抑制剂及使用方法
RU2435763C2 (ru) 2006-06-27 2011-12-10 Дзе Проктер Энд Гэмбл Компани Ингибиторы тирозинфосфатазы белка человека и способы применения
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
ES2612258T3 (es) 2006-10-27 2017-05-16 Sunnybrook Health Sciences Center Agonistas multiméricos de Tie 2 y usos de los mismos en la estimulación de la angiogénesis
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
WO2009105774A2 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
CN109771421A (zh) 2009-01-12 2019-05-21 爱尔皮奥治疗有限公司 治疗血管渗漏综合征的方法
KR20110123789A (ko) 2009-03-03 2011-11-15 알콘 리서치, 리미티드 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
AU2010221369B2 (en) 2009-03-03 2014-03-13 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
CN102365024A (zh) 2009-07-06 2012-02-29 阿克比治疗有限公司 用于防止癌细胞转移的化合物、组合物和方法
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
WO2011057112A1 (en) 2009-11-06 2011-05-12 Akebia Therapeutics Inc. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
ES2649340T3 (es) 2010-07-12 2018-01-11 Threshold Pharmaceuticals, Inc. Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
NZ610230A (en) 2010-10-07 2015-07-31 Aerpio Therapeutics Inc Compositions and methods for treating ocular edema, neovascularization and related diseases
CN103249422A (zh) 2010-12-02 2013-08-14 丸善制药株式会社 Tie2活化剂、血管内皮生长因子抑制剂、血管生成抑制剂、血管成熟剂、血管正常化剂及血管稳定剂、以及药物组合物
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
MX347226B (es) 2011-10-13 2017-04-19 Aerpio Therapeutics Inc Tratamiento de enfermedad ocular.
US20130190324A1 (en) 2011-12-23 2013-07-25 The Regents Of The University Of Colorado, A Body Corporate Topical ocular drug delivery
WO2013155512A2 (en) 2012-04-13 2013-10-17 The Johns Hopkins University Treatment of ischemic retinopathies
HRP20181124T1 (hr) 2012-07-31 2018-11-02 The Board Of Regents Of The University Of Texas System Postupci i pripravci za in vivo indukciju nastajanja beta stanica gušterače
AU2013328782C1 (en) 2012-10-11 2018-01-18 Ascendis Pharma Ophthalmology Division A/S VEGF neutralizing prodrugs for the treatment of ocular conditions
CA3121763A1 (en) 2012-11-08 2014-05-15 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US20150290235A1 (en) 2012-11-23 2015-10-15 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
HK1219836A1 (zh) 2013-03-15 2017-04-21 Aerpio Therapeutics, Inc. 用於治療眼病的組合物、製劑和方法
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CA2909080C (en) 2013-04-11 2022-07-26 Sunnybrook Research Institute Methods, uses and compositions of tie2 agonists
EP3010526A1 (en) 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating macular edema
EP3010525A1 (en) 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating choroidal neovascularisation
US20160151410A1 (en) 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
JP2016528202A (ja) 2013-07-11 2016-09-15 ノバルティス アーゲー 小児患者の脈絡網膜血管新生障害および透過性障害の治療におけるｖｅｇｆアンタゴニストの使用
AU2014288847A1 (en) 2013-07-11 2016-01-28 Novartis Ag Use of a VEGF antagonist in treating retinopathy of prematurity
US9828422B2 (en) 2013-07-29 2017-11-28 Samsung Electronics Co., Ltd. Anti-Ang2 antibody
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
CA2925936A1 (en) 2013-10-01 2015-04-09 Sphingotec Gmbh A method for predicting the risk of getting a major adverse cardiac event
RS59000B1 (sr) 2013-11-01 2019-08-30 Regeneron Pharma Intervencije zasnovane na angiopoietinu za lečenje cerebralne malarije
US9388135B2 (en) 2014-02-19 2016-07-12 Aerpio Therapeutics, Inc. Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
JP2015199733A (ja) 2014-04-04 2015-11-12 国立大学法人東北大学 眼圧降下剤
US9719135B2 (en) 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
US20160082129A1 (en) 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CN108290057A (zh) 2015-09-23 2018-07-17 爱尔皮奥治疗有限公司 用tie-2的激活剂治疗眼内压的方法
JP7107914B2 (ja) 2016-07-20 2022-07-27 アイポイント ファーマシューティカルズ， インコーポレイテッド ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体

Also Published As

Publication number Publication date
USRE46592E1 (en) 2017-10-31
KR101155365B1 (ko) 2012-06-20
US20180221346A1 (en) 2018-08-09
US20130324558A1 (en) 2013-12-05
RU2009102516A (ru) 2010-08-10
US9126958B2 (en) 2015-09-08
ES2650598T3 (es) 2018-01-19
IL196128A (en) 2013-08-29
PL2041102T3 (pl) 2015-03-31
ES2525429T3 (es) 2014-12-22
ZA200900559B (en) 2010-06-30
DK2041102T3 (en) 2014-12-15
HK1129386A1 (en) 2009-11-27
EP3323815B8 (en) 2020-12-30
EP2592072B1 (en) 2017-09-20
DK2592072T3 (en) 2017-12-04
JP5232778B2 (ja) 2013-07-10
US8258311B2 (en) 2012-09-04
PT3323815T (pt) 2021-01-13
JP2013127006A (ja) 2013-06-27
ES2846154T3 (es) 2021-07-28
PT2592072T (pt) 2017-12-11
CN101506183B (zh) 2012-08-08
US10463650B2 (en) 2019-11-05
US8895563B2 (en) 2014-11-25
US8946232B2 (en) 2015-02-03
EP2041102B1 (en) 2014-11-12
EP3323815A1 (en) 2018-05-23
US20220117946A1 (en) 2022-04-21
WO2008002569A3 (en) 2008-02-14
AU2007265453A1 (en) 2008-01-03
RU2447065C2 (ru) 2012-04-10
US7622593B2 (en) 2009-11-24
EP2592072A3 (en) 2013-05-29
AU2007265453B2 (en) 2012-01-19
US20160374996A1 (en) 2016-12-29
EP2592072A2 (en) 2013-05-15
JP2009542658A (ja) 2009-12-03
SI2041102T1 (sl) 2015-01-30
JP5860427B2 (ja) 2016-02-16
NZ574407A (en) 2012-02-24
US20200253936A1 (en) 2020-08-13
CA2657096C (en) 2014-01-21
AU2007265453A2 (en) 2009-07-09
US20140221666A1 (en) 2014-08-07
US20130096140A1 (en) 2013-04-18
DK3323815T3 (en) 2021-01-11
WO2008002569A2 (en) 2008-01-03
US20080108631A1 (en) 2008-05-08
CA2657096A1 (en) 2008-01-03
MX2009000288A (es) 2009-03-20
US20100016336A1 (en) 2010-01-21
CO6150144A2 (es) 2010-04-20
US20100069448A1 (en) 2010-03-18
US20150210656A1 (en) 2015-07-30
PL3323815T3 (pl) 2021-04-19
EP3323815B1 (en) 2020-10-07
US9795594B2 (en) 2017-10-24
US20220378750A1 (en) 2022-12-01
KR20090024819A (ko) 2009-03-09
PT2041102E (pt) 2014-12-22
IL196128A0 (en) 2009-09-22
BRPI0713570A2 (pt) 2012-10-30
EP2041102A2 (en) 2009-04-01
CN101506183A (zh) 2009-08-12
US9284285B2 (en) 2016-03-15

Similar Documents

Publication Publication Date Title
PT2592072T (pt) Inibidores de proteína tirosina fosfatase humana e sua utilização
PL2803663T3 (pl) Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne
IL196129A0 (en) Human protein tyrosine phosphatase inhibitors and methods of use
IL262205A (en) Protein formulations and methods for their preparation
ZA200807278B (en) Antibodies against human IL-22 and uses therefor
IL207415A0 (en) Protein kinase inhibitors and use thereof
ZA201003420B (en) Protein kinase inhibitors and use thereof
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
EP1922086A4 (en) TARGETED PROTEIN KINASE C HEMMER AND ITS USES
GB0722996D0 (en) Depsipeptides and their therapeutic use
EP1812012A4 (en) PROTEIN TYROSINE PHOSPHATASE INHIBITOR AND METHOD FOR THEIR USE
EP2045245A4 (en) IRREVERSIBLE TYROSINE KYNASES INHIBITORS AND METHODS OF PREPARATION AND USES THEREOF
ZA200900492B (en) Human protein tyrosine phosphatase inhibitors and methods of use
BRPI0719997A2 (pt) Uso de epotilonas no tratamento de osteoporose e doenças relacionadas
GB0614911D0 (en) New protein isoforms and uses thereof
IL198079A0 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases